Last updated: 2026-10-13 06:20:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Xencor, Inc. (XNCR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $25.05, with a market capitalisation of $1.83B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $10.38 to $30.61. This page covers its latest market performance, valuation, price trends and company information.
$1.83B | |
$24.64 | |
$58.35 | |
$5.75 | |
$24.63 | |
565.93K | |
1.34M | |
-- | |
$30.61 | |
$10.38 | |
-- | |
-- |
Xencor, Inc. (XNCR) last closed at $24.63 as of 2026-10-12 23:58:00, unchanged from the previous close of $24.63.
During the latest regular trading session, XNCR traded between $5.75 and $58.35, with a volume of 565.93K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Xencor, Inc. (XNCR) moved from $24.84 to $25.05, representing a gain of 0.83% ($0.21).
The stock traded between $22.56 and $26.03 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 1.34 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 72.5%
XNCR is currently trading at $25.05, placing it 72.5% of the way from its 52-week low of $10.38 to its 52-week high of $30.61. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 260 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Xencor, Inc. (XNCR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.